BioGPS
  • Home
  • Help
  • Plugins
  • Datasets
  • Sign Up
  • Login
Examples: Gene Symbol(s), Gene Ontology, Splicing plugins, Melanoma datasets
advanced
Home › Dataset Library › Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities

Dataset: Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities

Atopic dermatitis (AD) is a common inflammatory skin disease with a T(H)2 and T22 immune polarity. Despite recent data showing a genetic...

Registered by ArrayExpress Uploader
View Dataset

Atopic dermatitis (AD) is a common inflammatory skin disease with a T(H)2 and T22 immune polarity. Despite recent data showing a genetic predisposition to epidermal barrier defects in some patients, a fundamental debate still exists regarding the role of barrier abnormalities versus immune responses in initiating the disease. An extensive study of nonlesional AD (ANL) skin is necessary to explore whether there is an intrinsic predisposition to barrier abnormalities, background immune activation, or both in patients with AD. We sought to characterize ANL skin by determining whether epidermal differentiation and immune abnormalities that characterize lesional AD (AL) skin are also reflected in ANL skin. We performed genomic and histologic profiling of both ANL and AL skin lesions (n = 12 each) compared with normal human skin (n = 10). We found that ANL skin is clearly distinct from normal skin with respect to terminal differentiation and some immune abnormalities and that it has a cutaneous expansion of T cells. We also showed that ANL skin has a variable immune phenotype, which is largely determined by disease extent and severity. Whereas broad terminal differentiation abnormalities were largely similar between involved and uninvolved AD skin, perhaps accounting for the background skin phenotype, increased expression of immune-related genes was among the most obvious differences between AL and ANL skin, potentially reflecting the clinical disease phenotype. Our study implies that systemic immune activation might play a role in alteration of the normal epidermal phenotype, as suggested by the high correlation in expression of immune genes in ANL skin with the disease severity index. Genomic profile of paired samples of ANL and AL skin lesions from 12 patients compared with normal human skin (n = 8). For some patients, only 1 sample was available.

Species:
human

Samples:
33

Source:
E-GEOD-32924

PubMed:
21388663

Updated:
Dec.12, 2014

Registered:
Sep.16, 2014


Factors: (via ArrayExpress)
Sample INDIVIDUAL ECZEMA SEVERITY CONDITION
GSM815426 Patient P10 SCORAD: 0 ANL
GSM815427 Patient P10 SCORAD: 37 AL
GSM815428 Patient P13 SCORAD: 0 ANL
GSM815429 Patient P13 SCORAD: 51 AL
GSM815430 Patient P1 SCORAD: 0 ANL
GSM81543 Patient P1 SCORAD: 36 AL
GSM815432 Patient P14 SCORAD: 0 ANL
GSM815433 Patient P14 SCORAD: 33 AL
GSM815434 Patient P5 SCORAD: 0 ANL
GSM815435 Patient P5 SCORAD: 57 AL
GSM815436 Patient P7 SCORAD: 0 ANL
GSM815437 Patient P7 SCORAD: 56 AL
GSM815438 Patient P9 SCORAD: 55 AL
GSM815439 Patient P2 SCORAD: 0 ANL
GSM815440 Patient P2 SCORAD: 28 AL
GSM81544 Patient P8 SCORAD: 0 ANL
GSM815442 Patient P11 SCORAD: 64 AL
GSM815443 Patient P6 SCORAD: 0 ANL
GSM815444 Patient P6 SCORAD: 70 AL
GSM815445 Patient P12 SCORAD: 0 ANL
GSM815446 Patient P12 SCORAD: 91.1 AL
GSM815447 Patient P3 SCORAD: 0 ANL
GSM815448 Patient P3 SCORAD: 81 AL
GSM815449 Patient P4 SCORAD: 0 ANL
GSM815450 Patient P4 SCORAD: 97.5 AL
GSM81545 Patient N-1 SCORAD: 0 normal
GSM815452 Patient N-2 SCORAD: 0 normal
GSM815453 Patient N-3 SCORAD: 0 normal
GSM815454 Patient N-4 SCORAD: 0 normal
GSM815455 Patient N-5 SCORAD: 0 normal
GSM815456 Patient N-6 SCORAD: 0 normal
GSM815457 Patient N-7 SCORAD: 0 normal
GSM815458 Patient N-8 SCORAD: 0 normal

Tags

  • atopic dermatitis
  • dermatitis
  • disease
  • skin
  • skin disease

Other Formats

JSON    XML
  • About
  • Blog
  • Help
  • FAQ
  • Downloads
  • API
  • iPhone App
  • Email updates
© 2023 The Scripps Research Institute. All rights reserved. (ver 94eefe6 )
  • Terms of Use